Why the study?
Patients with a history of Takotsubo cardiomyopathy receiving cardiotoxic chemotherapy such as FOLFOX require vigilant monitoring, and strategies for minimizing cardiotoxic risk during 5-fluorouracil rechallenge need consideration.
Design
Case report
Follow-up
One month
Authors
Loading...
Draft 1:* Suggests vigilant cardiac monitoring is necessary when administering FOLFOX to.
This case demonstrates that patients who develop Takotsubo cardiomyopathy after 5-fluorouracil infusion may be safely rechallenged under close cardiac surveillance.
Raizada et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: